Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Viking Therapeutics, Inc. (VKTX) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -54,256,000 | 20.07 M | 368.49 M | 367.23 M | |
| 2022 | -35,068,000 | 23.21 M | 168.53 M | 167.04 M | |
| 2021 | -26,342,000 | 8.78 M | 210.66 M | 210.53 M | |
| 2020 | -28,758,000 | 12.16 M | 256.5 M | 256.1 M | |
| 2019 | -7,715,000 | 7.14 M | 284.26 M | 283.5 M |